Jazz Pharmaceuticals (JAZZ) Short Interest Ratio & Short Volume $109.13 +1.53 (+1.42%) Closing price 04:00 PM EasternExtended Trading$110.43 +1.30 (+1.19%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Jazz Pharmaceuticals Short Interest DataJazz Pharmaceuticals (JAZZ) has a short interest of 5.83 million shares, representing 10.11% of the float (the number of shares available for trading by the public). This marks a 2.10% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.0, indicating that it would take 5.0 days of the average trading volume of 829,274 shares to cover all short positions.Current Short Interest5,830,000 sharesPrevious Short Interest5,710,000 sharesChange Vs. Previous Month+2.10%Dollar Volume Sold Short$632.56 millionShort Interest Ratio5.0 Days to CoverLast Record DateJune 15, 2025Outstanding Shares60,510,000 sharesFloat Size57,660,000 sharesShort Percent of Float10.11%Today's Trading Volume1,064,571 sharesAverage Trading Volume829,274 sharesToday's Volume Vs. Average128% Short Selling Jazz Pharmaceuticals? Sign up to receive the latest short interest report for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartJAZZ Short Interest Over TimeJAZZ Days to Cover Over TimeJAZZ Percentage of Float Shorted Over Time Jazz Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20255,830,000 shares $632.56 million +2.1%10.1%5 $108.50 5/31/20255,710,000 shares $618.28 million -4.0%9.7%4.5 $108.28 5/15/20255,950,000 shares $631.12 million +11.2%10.1%4.4 $106.07 4/30/20255,350,000 shares $625.74 million +18.1%9.1%4.1 $116.96 4/15/20254,530,000 shares $466.18 million +5.8%7.8%4 $102.91 3/31/20254,280,000 shares $531.36 million -5.3%7.4%4.2 $124.15 3/15/20254,520,000 shares $623.58 million +3.7%7.8%5.4 $137.96 2/28/20254,360,000 shares $625.79 million -3.8%7.5%6 $143.53 2/15/20254,530,000 shares $606.84 million +7.4%7.9%7 $133.96 1/31/20254,220,000 shares $524.84 million -0.9%7.3%6.8 $124.37 Get the Latest News and Ratings for JAZZ and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20254,260,000 shares $525.00 million +10.7%7.4%7.2 $123.24 12/31/20243,850,000 shares $474.13 million -8.3%6.7%6.4 $123.15 12/15/20244,200,000 shares $516.77 million -1.2%7.3%6.9 $123.04 11/30/20244,250,000 shares $516.76 million +11.3%7.3%7 $121.59 11/15/20243,820,000 shares $464.70 million +6.4%6.6%5.4 $121.65 10/31/20243,590,000 shares $395.01 million +2.9%6.2%5.5 $110.03 10/15/20243,490,000 shares $409.31 million +3.3%5.9%5.1 $117.28 9/30/20243,380,000 shares $376.57 million +3.1%5.7%5.1 $111.41 9/15/20243,280,000 shares $356.83 million +73.5%5.5%4.8 $108.79 8/31/20241,890,000 shares $219.20 million -7.4%3.2%2.7 $115.98 8/15/20242,040,000 shares $224.40 million -10.9%3.4%2.8 $110.00 7/31/20242,290,000 shares $252.47 million -17.6%3.8%3 $110.25 7/15/20242,780,000 shares $287.26 million +3.7%N/A3.7 $103.33 6/30/20242,680,000 shares $286.04 million +4.7%N/A3.5 $106.73 6/15/20242,560,000 shares $289.05 million -24.9%N/A3.4 $112.91 5/31/20243,410,000 shares $358.90 million +4.0%N/A4.6 $105.25 5/15/20243,280,000 shares $359.95 million -8.9%N/A4.8 $109.74 4/30/20243,600,000 shares $398.70 million -2.7%N/A5.6 $110.75 4/15/20243,700,000 shares $410.37 million +13.5%6.1%6 $110.91 3/31/20243,260,000 shares $392.57 million +17.7%5.4%5.3 $120.42 3/15/20242,770,000 shares $334.89 million +15.9%4.6%4.3 $120.90 2/29/20242,390,000 shares $284.17 million +3.0%4.0%4 $118.90 2/15/20242,320,000 shares $294.22 million +5.0%N/A4 $126.82 1/31/20242,210,000 shares $271.21 million +2.3%N/A3.4 $122.72 1/15/20242,160,000 shares $256.91 million -1.8%N/A3 $118.94 12/31/20232,200,000 shares $270.60 million -0.5%N/A3.1 $123.00 12/15/20232,210,000 shares $268.52 million -9.1%N/A3.1 $121.50 11/30/20232,430,000 shares $287.30 million -5.5%N/A3.6 $118.23 11/15/20232,570,000 shares $322.28 million -6.2%N/A4 $125.40 10/31/20232,740,000 shares $348.03 million +5.0%N/A4.5 $127.02Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 10/15/20232,610,000 shares $337.00 million -19.9%N/A4.7 $129.12 9/30/20233,260,000 shares $421.97 million -2.4%N/A6.9 $129.44 9/15/20233,340,000 shares $442.52 million +16.8%N/A6.8 $132.49 8/31/20232,860,000 shares $410.01 million +1.1%N/A5.4 $143.36 8/15/20232,830,000 shares $396.17 million -0.4%N/A5 $139.99 7/31/20232,840,000 shares $370.39 million -5.7%N/A5 $130.42 7/15/20233,010,000 shares $381.34 million +0.3%N/A5.3 $126.69 6/30/20233,000,000 shares $371.91 million +11.5%N/A5.4 $123.97 6/15/20232,690,000 shares $346.82 million -13.8%N/A5.1 $128.93 5/31/20233,120,000 shares $399.86 million +5.1%N/A6.3 $128.16 5/15/20232,970,000 shares $400.00 million +19.8%N/A6 $134.68 4/30/20232,480,000 shares $348.37 million +7.4%N/A5 $140.47 4/15/20232,310,000 shares $336.15 million -10.1%N/A4.8 $145.52 3/31/20232,570,000 shares $376.07 million +10.8%N/A5 $146.33 3/15/20232,320,000 shares $312.94 million -4.9%N/A4.4 $134.89 2/28/20232,440,000 shares $342.58 million -1.6%N/A4.2 $140.40 2/15/20232,480,000 shares $370.54 million -3.9%N/A4.6 $149.41 1/31/20232,580,000 shares $404.18 million -1.9%N/A4.6 $156.66 1/15/20232,630,000 shares $411.52 million -2.6%N/A4.8 $156.47 12/30/20222,700,000 shares $430.14 million +21.1%N/A5 $159.31 12/15/20222,230,000 shares $341.10 million +2.8%N/A4 $152.96 11/30/20222,170,000 shares $340.49 million -7.7%N/A4 $156.91 11/15/20222,350,000 shares $348.83 million -1.7%N/A4.5 $148.44 10/31/20222,390,000 shares $343.66 million +6.2%N/A4.7 $143.79 10/15/20222,250,000 shares $299.72 million -14.1%N/A4.3 $133.21 9/30/20222,620,000 shares $349.22 million -4.4%N/A5 $133.29 9/15/20222,740,000 shares $416.97 million -1.4%N/A5.3 $152.18 8/31/20222,780,000 shares $431.51 million No ChangeN/A5.7 $155.22 8/15/20222,780,000 shares $445.52 million +3.0%N/A5.4 $160.26 7/31/20222,700,000 shares $421.36 million -9.7%4.5%5.2 $156.06 7/15/20222,990,000 shares $470.75 million +2.8%4.9%5.8 $157.44 6/30/20222,910,000 shares $453.99 million -4.9%4.8%5.4 $156.01 6/15/20223,060,000 shares $446.09 million -13.8%5.1%5.5 $145.78 5/31/20223,550,000 shares $531.36 million +10.6%5.9%6.7 $149.68 5/15/20223,210,000 shares $470.23 million -2.7%5.3%5.5 $146.49 4/30/20223,300,000 shares $528.73 million -12.2%5.6%5.6 $160.22 4/15/20223,760,000 shares $628.86 million +4.7%6.3%6.6 $167.25 3/31/20223,590,000 shares $558.86 million -5.0%6.0%5.7 $155.67 3/15/20223,780,000 shares $584.88 million -6.9%6.3%6.2 $154.73 2/28/20224,060,000 shares $557.93 million -6.0%6.8%6.4 $137.42 2/15/20224,320,000 shares $624.11 million +0.9%7.2%7 $144.47 1/31/20224,280,000 shares $594.53 million +3.9%7.2%6.9 $138.91 1/15/20224,120,000 shares $594.52 million -7.2%6.9%6.7 $144.30 12/31/20214,440,000 shares $565.66 million +0.7%7.4%7.4 $127.40 12/15/20214,410,000 shares $536.83 million +9.7%7.4%7.4 $121.73 11/30/20214,020,000 shares $481.88 million -2.7%6.7%6.4 $119.87 11/15/20214,130,000 shares $574.81 million +7.8%6.9%6.6 $139.18 10/29/20213,830,000 shares $509.54 million No Change6.4%5.8 $133.04 10/15/20213,830,000 shares $538.88 million +7.6%6.4%5.4 $140.70 9/30/20213,560,000 shares $463.55 million -1.1%6.0%5 $130.21Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad)Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. For the moment, you can watch this interview free of charge – just click here. 9/15/20213,600,000 shares $479.52 million -3.0%6.1%5.4 $133.20 8/31/20213,710,000 shares $488.64 million -12.9%6.2%5.4 $131.71 8/13/20214,260,000 shares $605.60 million +1.2%7.2%6.4 $142.16 7/30/20214,210,000 shares $713.68 million +2.2%7.1%6.5 $169.52 7/15/20214,120,000 shares $735.21 million +3.0%7.0%6.2 $178.45 6/30/20214,000,000 shares $710.56 million -11.3%6.8%6 $177.64 6/15/20214,510,000 shares $827.18 million +15.6%7.7%6.7 $183.41 5/28/20213,900,000 shares $694.71 million +8.0%6.7%6.2 $178.13 5/14/20213,610,000 shares $643.16 million -31.4%N/A5.4 $178.16 4/30/20215,260,000 shares $871.85 million +11.2%N/A7.4 $165.75 4/15/20214,730,000 shares $786.93 million +0.6%8.7%6.5 $166.37 3/31/20214,700,000 shares $782.50 million +3.8%8.7%6.5 $166.49 3/15/20214,530,000 shares $758.87 million +4.4%8.4%6.2 $167.52 2/26/20214,340,000 shares $741.01 million +5.3%8.0%6 $170.74 2/12/20214,120,000 shares $687.42 million +30.0%7.6%6 $166.85 1/29/20213,170,000 shares $517.50 million -2.2%5.8%5 $163.25 1/15/20213,240,000 shares $537.22 million -6.4%6.0%6.2 $165.81 12/31/20203,460,000 shares $569.38 million -0.6%6.4%6.7 $164.56 12/15/20203,480,000 shares $519.32 million -4.7%6.5%6.6 $149.23 11/30/20203,650,000 shares $522.97 million +1.1%6.8%5.1 $143.28 11/15/20203,610,000 shares $531.07 million -11.1%6.7%4.8 $147.11 10/30/20204,060,000 shares $591.26 million -2.6%7.6%5.5 $145.63 10/15/20204,170,000 shares $634.67 million -12.4%7.8%5.5 $152.20 9/30/20204,760,000 shares $678.73 million +30.4%8.9%6.1 $142.59 9/15/20203,650,000 shares $516.48 million +13.0%6.8%4.7 $141.50 8/31/20203,230,000 shares $434.08 million +4.5%6.1%4.7 $134.39 8/14/20203,090,000 shares $383.96 million -11.5%5.8%4.4 $124.26 7/31/20203,490,000 shares $377.79 million +0.9%6.5%5 $108.25 7/15/20203,460,000 shares $378.73 million -5.0%6.5%5.2 $109.46 JAZZ Short Interest - Frequently Asked Questions What is Jazz Pharmaceuticals' current short interest? Short interest is the volume of Jazz Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 5,830,000 shares of JAZZ short. 10.11% of Jazz Pharmaceuticals' shares are currently sold short. Learn More on Jazz Pharmaceuticals' current short interest. What is a good short interest ratio for Jazz Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. JAZZ shares currently have a short interest ratio of 5.0. Learn More on Jazz Pharmaceuticals's short interest ratio. Which institutional investors are shorting Jazz Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Jazz Pharmaceuticals: Quaker Wealth Management LLC, Jane Street Group LLC, Jane Street Group LLC, Simplex Trading LLC, Wolverine Asset Management LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Jazz Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.11% of Jazz Pharmaceuticals' floating shares are currently sold short. Is Jazz Pharmaceuticals' short interest increasing or decreasing? Jazz Pharmaceuticals saw a increase in short interest in June. As of June 15th, there was short interest totaling 5,830,000 shares, an increase of 2.1% from the previous total of 5,710,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Jazz Pharmaceuticals' float size? Jazz Pharmaceuticals currently has issued a total of 60,511,000 shares. Some of Jazz Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Jazz Pharmaceuticals currently has a public float of 57,660,000 shares. How does Jazz Pharmaceuticals' short interest compare to its competitors? 10.11% of Jazz Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Jazz Pharmaceuticals: Axsome Therapeutics, Inc. (10.51%), Royalty Pharma PLC (8.74%), Corcept Therapeutics Incorporated (13.49%), Perrigo Company plc (3.63%), Supernus Pharmaceuticals, Inc. (7.61%), Pacira BioSciences, Inc. (12.92%), Nektar Therapeutics (4.98%), Omeros Corporation (23.40%), Assembly Biosciences, Inc. (0.41%), Cumberland Pharmaceuticals Inc. (0.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Jazz Pharmaceuticals stock? Short selling JAZZ is an investing strategy that aims to generate trading profit from Jazz Pharmaceuticals as its price is falling. JAZZ shares are trading up $3.25 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Jazz Pharmaceuticals? A short squeeze for Jazz Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of JAZZ, which in turn drives the price of the stock up even further. How often is Jazz Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including JAZZ, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies AXSM Short Interest Data RPRX Short Interest Data CORT Short Interest Data PRGO Short Interest Data SUPN Short Interest Data PCRX Short Interest Data NKTR Short Interest Data OMER Short Interest Data ASMB Short Interest Data CPIX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:JAZZ) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JAZZ Stock Alerts